391 related articles for article (PubMed ID: 32335802)
21. Pharmacokinetic of berberine, the main constituent of Berberis vulgaris L.: A comprehensive review.
Khoshandam A; Imenshahidi M; Hosseinzadeh H
Phytother Res; 2022 Nov; 36(11):4063-4079. PubMed ID: 36221815
[TBL] [Abstract][Full Text] [Related]
22. A Natural Isoquinoline Alkaloid With Antitumor Activity: Studies of the Biological Activities of Berberine.
Liu D; Meng X; Wu D; Qiu Z; Luo H
Front Pharmacol; 2019; 10():9. PubMed ID: 30837865
[TBL] [Abstract][Full Text] [Related]
23. [Investigation on pattern and methods of quality control for Chinese materia medica based on dao-di herbs and bioassay - bioassay for Coptis chinensis].
Yan D; Xiao XH
Yao Xue Xue Bao; 2011 May; 46(5):568-72. PubMed ID: 21800546
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of activator protein 1 activity by berberine in human hepatoma cells.
Fukuda K; Hibiya Y; Mutoh M; Koshiji M; Akao S; Fujiwara H
Planta Med; 1999 May; 65(4):381-3. PubMed ID: 10364850
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of contents of berberine in Coptis chinensis of Lichuan].
Guo ZG; Lin Z; Sun RQ; Sun SQ; Wang LQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Dec; 26(6):618-21. PubMed ID: 15663219
[TBL] [Abstract][Full Text] [Related]
26. [Study on metabolism of Coptis chinensis alkaloids from different compatibility of Wuji Wan in human intestinal flora].
Men W; Chen Y; Yang Q; Li YJ; Gong ZP; Weng XG; Wang YJ; Zhang RJ; Zhu XX
Zhongguo Zhong Yao Za Zhi; 2013 Feb; 38(3):417-21. PubMed ID: 23668021
[TBL] [Abstract][Full Text] [Related]
27. Antihyperglycemic effect of the traditional Chinese scutellaria-coptis herb couple and its main components in streptozotocin-induced diabetic rats.
Liu SZ; Deng YX; Chen B; Zhang XJ; Shi QZ; Qiu XM
J Ethnopharmacol; 2013 Jan; 145(2):490-8. PubMed ID: 23183087
[TBL] [Abstract][Full Text] [Related]
28. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest.
Kim JB; Yu JH; Ko E; Lee KW; Song AK; Park SY; Shin I; Han W; Noh DY
Phytomedicine; 2010 May; 17(6):436-40. PubMed ID: 19800775
[TBL] [Abstract][Full Text] [Related]
29. Microarray expression profiling of Yersinia pestis in response to berberine.
Zhang J; Zuo G; Bai Q; Wang Y; Yang R; Qiu J
Planta Med; 2009 Mar; 75(4):396-8. PubMed ID: 19053015
[TBL] [Abstract][Full Text] [Related]
30. Exploration of anti-cancer effects and mechanisms of Zuo-Jin-Wan and its alkaloid components in vitro and in orthotopic HepG2 xenograft immunocompetent mice.
Chou ST; Hsiang CY; Lo HY; Huang HF; Lai MT; Hsieh CL; Chiang SY; Ho TY
BMC Complement Altern Med; 2017 Feb; 17(1):121. PubMed ID: 28219365
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications.
Tian E; Sharma G; Dai C
Antioxidants (Basel); 2023 Oct; 12(10):. PubMed ID: 37891961
[TBL] [Abstract][Full Text] [Related]
32. Berberine inhibits intestinal epithelial barrier dysfunction in colon caused by peritoneal dialysis fluid by improving cell migration.
Zhang D; Jiang L; Wang M; Jin M; Zhang X; Liu D; Wang Z; Yang L; Xu X
J Ethnopharmacol; 2021 Jan; 264():113206. PubMed ID: 32750460
[TBL] [Abstract][Full Text] [Related]
33. Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation.
Auyeung KK; Ko JK
Int J Mol Med; 2009 Oct; 24(4):571-7. PubMed ID: 19724899
[TBL] [Abstract][Full Text] [Related]
34. Berberine pharmacology and the gut microbiota: A hidden therapeutic link.
Habtemariam S
Pharmacol Res; 2020 May; 155():104722. PubMed ID: 32105754
[TBL] [Abstract][Full Text] [Related]
35. Berberine and inflammatory bowel disease: A concise review.
Habtemariam S
Pharmacol Res; 2016 Nov; 113(Pt A):592-599. PubMed ID: 27697643
[TBL] [Abstract][Full Text] [Related]
36. [Research development of Coptis chinensis].
Xu JT; Wang LQ; Xu B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Dec; 26(6):704-7. PubMed ID: 15663237
[TBL] [Abstract][Full Text] [Related]
37. Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine.
Wang S; Xu Z; Cai B; Chen Q
Endocr Metab Immune Disord Drug Targets; 2021; 21(6):971-979. PubMed ID: 32914727
[TBL] [Abstract][Full Text] [Related]
38. An Updated Review on Therapeutic Potential and Recent Advances in Drug Delivery of Berberine: Current Status and Future Prospect.
Mujtaba MA; Akhter MH; Alam MS; Ali MD; Hussain A
Curr Pharm Biotechnol; 2022; 23(1):60-71. PubMed ID: 33557735
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of vascular smooth muscle cell proliferation by coptisine isolated from Coptis rhizoma, one of the crude drugs composing Kampo medicines Unsei-in.
Tanabe H; Suzuki H; Nagatsu A; Mizukami H; Ogihara Y; Inoue M
Phytomedicine; 2006 May; 13(5):334-42. PubMed ID: 16635741
[TBL] [Abstract][Full Text] [Related]
40. [Research progress on chemical compositions of Coptidis Rhizoma and pharmacological effects of berberine].
Rui Z; Chang-Pei X; Jing-Jing Z; Hong-Jun Y
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(19):4561-4573. PubMed ID: 33164419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
